Gilead Sciences Inc. [NASDAQ: GILD] slipped around -0.42 points on Wednesday, while shares priced at $63.91 at the close of the session, down -0.65%. The company report on March 9, 2021 that Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI.
– Lenacapavir Maintained High Rates of Virologic Suppression Among Heavily Treatment-Experienced People with Multi-Drug Resistant HIV –.
– Late-Breaking Preclinical Data Support Further Study of Lenacapavir as a Long-Acting Agent for HIV Prevention –.
Gilead Sciences Inc. stock is now 9.70% up from its year-to-date (YTD) trading value. GILD Stock saw the intraday high of $64.80 and lowest of $63.60 per share. The company’s 52-week high price is 85.97, which means current price is +10.32% above from all time high which was touched on 02/05/21.
Compared to the average trading volume of 9.26M shares, GILD reached a trading volume of 7480449 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $74.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 19, 2021. The new note on the price target was released on January 04, 2021, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $67, while Morgan Stanley analysts kept a Equal-Weight rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.58, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.18. The Price to Book ratio for the last quarter was 4.41, with the Price to Cash per share for the same quarter was set at 6.02. Price to Free Cash Flow for GILD in the course of the last twelve months was 19.31 with Quick ratio for the last quarter at 1.30.
How has GILD stock performed recently?
Gilead Sciences Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.85. With this latest performance, GILD shares dropped by -5.97% in over the last four-week period, additionally sinking by -0.36% over the last 6 months – not to mention a drop of -11.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 48.71, with the RSI for the last a single of trading hit 48.57, and the three-weeks RSI is set at 49.75 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 63.95, while it was recorded at 64.17 for the last single week of trading, and 66.13 for the last 200 days.
Gilead Sciences Inc. [GILD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +42.38 and a Gross Margin at +81.70. Gilead Sciences Inc.’s Net Margin is presently recorded at +0.50.
Return on Total Capital for GILD is now 21.25, given the latest momentum, and Return on Invested Capital for the company is 0.27. Return on Equity for this stock inclined to 0.60, with Return on Assets sitting at 0.19. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 176.45. Additionally, GILD Total Debt to Total Capital is recorded at 63.83, with Total Debt to Total Assets ending up at 46.95. Long-Term Debt to Equity for the company is recorded at 160.71, with the Long-Term Debt to Total Capital now at 58.14.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $9,044 per employee. Receivables Turnover for the company is 5.81 with a Total Asset Turnover recorded at a value of 0.38.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
Earnings analysis for Gilead Sciences Inc. [GILD]
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.68/share EPS, while the average EPS was predicted by analysts to be reported at 1.57/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 2.80%.
Insider trade positions for Gilead Sciences Inc. [GILD]
There are presently around $62,009 million, or 79.60% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 121,672,399, which is approximately 3.893% of the company’s market cap and around 0.11% of the total institutional ownership; BLACKROCK INC., holding 111,183,334 shares of the stock with an approximate value of $7.11 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.57 billion in GILD stock with ownership of nearly 0.063% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 720 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 51,608,952 shares. Additionally, 865 investors decreased positions by around 57,170,961 shares, while 145 investors held positions by with 861,468,920 shares. The mentioned changes placed institutional holdings at 970,248,833 shares, according to the latest SEC report filing. GILD stock had 193 new institutional investments in for a total of 6,470,023 shares, while 167 institutional investors sold positions of 6,029,324 shares during the same period.